Moberg Pharma ABmobergpharma.com/sites/default/files/mp_presentation_redeye_131… · Majority of...
15
Corporate Presentation – Redeye Life Science Conference, November 28, 2013 Peter Wolpert, CEO and Founder Moberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY
Transcript of Moberg Pharma ABmobergpharma.com/sites/default/files/mp_presentation_redeye_131… · Majority of...
Corporate Presentation – Redeye Life Science Conference, November 28, 2013
Peter Wolpert, CEO and Founder
Moberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY
Disclaimer
1
Statements included herein that are not historical
facts are forward-looking statements. Such forward-
looking statements involve a number of risks and
uncertainties and are subject to change at any time.
In the event such risks or uncertainties materialize,
Moberg Pharma’s results could be materially
affected.
The risks and uncertainties include, but are not
limited to, risks associated with the inherent
uncertainty of pharmaceutical research and product
development, manufacturing and commercialization,
the impact of competitive products, patents, legal
challenges, government regulation and approval,
Moberg Pharma’s ability to secure new products for
commercialization and/or development and other
risks and uncertainties detailed from time to time in
Moberg Pharma’s interim or annual reports,
prospectuses or press releases.
2
Moberg Pharma Building a different kind of pharma company
Strategic plan
Strategy to reach1 BSEK
in sales
Organic growth, M&A and
internal development
Build value through:
- Brand Equity, U.S. focus
- IP Equity
Vision
Build a mid-size Pharma and
Consumer Health company with
sales in the U.S. and select countries
in OTC and select specialty
indications
Financial goal: 25% EBITDA margin
with healthy growth
Focus on building shareholder value
Rapid growth 2010 – 2013, MSEK
3
2010 2011 2012 2013 Q1-Q3
82
+400%
+600%
+100%
+48% +92% growth
of product sales
Majority of revenue from proprietary sales
4
Sales via distributors
40%
Proprietary sales 60%
JointFlex 19%
Nalox/ Kerasal Nail
65%
Kerasal 16%
RoW 10%
Europe 29%
America 61%
Channels Products Geography
Distribution of revenue, Jan - Sept 2013
Portfolio of brands, products and projects
Current portfolio Future portfolio
Brands
Products sold
through partners
Pipeline
® ®
®
5
MOB-015
X Y Z +
X Y +
U.S. OTC operations – platform for building Brand Equity
Retailers/
Wholesalers Sales Force
Contract
Manufacturers
Logistics
Sales and marketing/Brand Management
6
A large aging population, steady to increased incidences of conditions and diseases, self
care & Rx to OTC switches fuel OTC market growth
U.S. Consumer spending on OTC health is expanding
Source: Nielsen Scantrack Total US xAOC 52 weeks ending CY2012. Projected estimate for 2013/2014 based on current growth rate.
$37,2 $38,4
$40,1
$42,1
$44,3
12/25/10 12/24/11 12/22/12 est. 2013 est. 2014
Total US Sales (billions)
+4.5% +3.2%
+4.9% +5.2%
CONFIDENTIAL
8
Q3 growth (value), percent
5%
26%
OTC market
Moberg U.S.
Significantly faster growth
than the market
Growth driver
Combination of Brand and
IP equity:
Available at 30 000 points of sale
Distribution added through Target,
Meijer and Hannaford
9
10% 19% market share increase last 12 months
Kerasal Nail™ – Best selling product in its category
10
Positive initial response on advertising and
the product from consumers and retailers
Walgreens increases distribution
21,000 stores at Walmart, CVS,
Walgreens, and Rite Aid
Ca 30 million Americans experience
frequent foot pain1. Many simultaneously
suffer from cold feet and dry skin.
Associated with diabetes, fibromyalgia,
arthritis, joint pain, muscle strain or trauma.
Triple action formula that relieves foot pain,
warms cold feet, and moisturizes dry skin.
Active ingredients: capsaicin and camphor,
Fusome® - skin delivery system
Launch of Kerasal® NeuroCream at Walmart and major U.S.
drugstores in September 2013
1 The population prevalence of foot and ankle pain in middle and old age: a systematic review. Thomas et al, Pain 2011 Dec
11
Organic growth
Current products growing, line extensions
- Kerasal NeuroCream™ launch started
Launches in new markets through
distributors
8 patent families enable additional products
- MOB-015
>100 NEW BUSINESS OPPORTUNITIES TO BE EVALUATED 2013 Acquisitions/inlicensing
Products - Focus on US OTC market
Projects and technologies
MOB 015 generates high TBF concentrations in nail
Phase II trial ongoing (fully recruited in May 2013)
12
Target profile for MOB-015
Low Medium High
High
Medium
Low
Efficacy
Existing
tablets MOB-015
Nalox™
Existing
topicals
Safety
Source: Hui, Maibach et al, Drug Development and Industrial Pharmacy, 2012; Franz cell experiments with human nail;
Amount TBF in the deeper part of the nail plate
** Schatz F, et al; Clin Exp Dermatol, 1995 Sep;20(5):377-83
Terbinafine concentration in human nail, µg/g nail
0,5
> 613
Oral terbinafine therapy** MOB-015*
Share development – from IPO to Nov 26, 2013 CONFIDENTIAL
13
14
Focus next 12 months Building a different kind of pharma company
Get to positive EBITDA!
Fuel strong U.S growth
- K-Nail and Neurocream launch
- Acquisitions of mature brands
Grow Distributor Sales
- Support current distributors
- Increase geographical reach
BD focus
- US OTC products
- Strengthen pipeline
MOB-015 phase II data and initiate licensing
process
